Orphan Drugs, 340B, and the Challenges of Implementing Health Reform
This article was originally published in RPM Report
Executive Summary
A proposed rule issued by HRSA probably changes prescription drug spending in the US by about .005%. But it will have an impact on almost every pharmaceutical company pricing department, and offers a valuable illustration of some of the bigger themes of implementing the reform law overall.